A South Kolkata Rabindra Jayanti celebration beautifully showcased inclusivity, uniting specially-abled and ...
Akeso, Inc. (9926.HK) (Akeso or the Company) today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meani ...
Updateddata across two dose levels of 200 mW/cm and 400 mW/cmin LA-PDAC trialshow71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results